Literature DB >> 19861429

Sorafenib-induced hepatic encephalopathy.

Anne-Bérengère Marks, Romain Gerard, Peggy Fournier, Patrick Coupe, Sophie Gautier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19861429     DOI： 10.1345/aph.1M457

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN： 1060-0280            Impact factor:   3.154


× No keyword cloud information.
  4 in total

Review 1.  Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Authors:  Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

2.  Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm.

Authors:  Claudia I Chapuy; Inderneel Sahai; Rohit Sharma; Andrew X Zhu; Olga N Kozyreva
Journal:  Oncologist       Date:  2016-03-14

3.  Hepatic encephalopathy associated with cancer or anticancer therapy.

Authors:  Kaspar J Willson; Louise M Nott; Vy T Broadbridge; Timothy Price
Journal:  Gastrointest Cancer Res       Date:  2013-01

4.  Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.

Authors:  Masahide Fukudo; Takuma Ito; Tomoyuki Mizuno; Keiko Shinsako; Etsuro Hatano; Shinji Uemoto; Tomomi Kamba; Toshinari Yamasaki; Osamu Ogawa; Hiroshi Seno; Tsutomu Chiba; Kazuo Matsubara
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.